An EU MedTech startup should hire a US regulatory consultant when it commits to a specific US pathway (510(k), De Novo or PMA), not before. Evaluate consultants on predicate-search rigour, QMSR transition experience, FDA interaction track record, and willingness to work on fixed-scope deliverables rather than open retainers. The right consultant earns back their fee by removing a single Refuse-to-Accept letter.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • Hire a US regulatory consultant only after you have a signed US commercial rationale and a target pathway, not during exploratory phase.
  • The three most common useful scopes are predicate research and 510(k) drafting, De Novo request preparation, and QMSR gap analysis against an existing ISO 13485 QMS.
  • Fixed-scope, fixed-price engagements beat hourly retainers for most startups; retainers make sense only during live FDA correspondence.
  • Red flags include promises of specific clearance timelines, refusal to share FDA correspondence from prior projects (redacted), and recommending a Pre-Submission for every device.
  • A good US consultant understands your existing MDR technical documentation and reuses it; a bad one asks you to start over.
  • Contract structure matters more than headline rate: milestone payments, defined deliverables, right to review Q-Sub responses before submission.

Why this matters

The moment an EU MedTech startup decides the US is a real market, the regulatory stack doubles. Your CE mark and MDR technical documentation cover Europe. The US needs its own classification analysis, its own predicate strategy (if going 510(k)), its own quality system alignment now that FDA has moved from 21 CFR 820 to the Quality Management System Regulation (QMSR), and its own labeling review. Most EU founders underestimate how different the FDA conversation feels compared to a Notified Body audit.

Hiring a US regulatory consultant is often the right move. It is also one of the easiest ways to waste 40,000 to 120,000 euros. The difference comes down to when you hire, what you scope, and how you evaluate the person sitting across the Zoom call.

This post is the checklist we wish more EU founders had before signing their first US RA consulting contract.

What FDA work actually looks like for an EU startup

Before evaluating consultants, be honest about what you need them to do. US regulatory work for an EU startup usually falls into one of these buckets:

Pathway selection and classification. Your device may be Class I (general controls, often 510(k) exempt), Class II (510(k) or sometimes De Novo), or Class III (PMA). US classification does not mirror EU classification. A Class IIa MDR device might be Class II in the US but can also be Class I exempt or Class III depending on the product code and intended use. This is the first place consultants earn their fee or waste your money.

Predicate search and 510(k) drafting. The 510(k) pathway requires substantial equivalence to a legally marketed predicate device. Finding the right predicate is a craft. It determines whether your submission sails through or bounces with a Refuse-to-Accept letter in the first 15 days.

De Novo request. When no suitable predicate exists but the risk profile is low-to-moderate, De Novo creates a new classification. It is more work than 510(k), less than PMA, and requires genuine clinical and engineering justification.

PMA preparation. Pre-Market Approval for Class III devices. This is a multi-year, multi-million-dollar effort. If you need PMA support, you do not need a consultant, you need a team.

QMSR alignment. FDA finalised the QMSR to harmonise its quality system requirements with ISO 13485:2016, with a transition deadline in early 2026. For EU startups already running a 13485-compliant QMS, QMSR is manageable but not free. A consultant can do the gap analysis in two to three weeks.

US Agent and labeling review. Every foreign establishment needs a US Agent. Labels need compliance with 21 CFR 801 and any device-specific requirements. This is often bundled into larger scopes.

Get clear on which of these you actually need before you start calling consultants. The worst engagements begin with a vague "we want to enter the US market."

MDR versus FDA in one paragraph

The framing difference matters. MDR is principles-based: you meet the General Safety and Performance Requirements in Annex I, demonstrate conformity through a chosen route, and a Notified Body reviews your technical documentation and QMS. FDA is pathway-based: you pick a submission type (510(k), De Novo, PMA), you meet specific content requirements for that submission, and FDA reviews the submission itself. A good US consultant translates between these two worlds without forcing you to rebuild your EU technical file from scratch. A bad one treats your MDR work as irrelevant.

A worked example

A Graz-based startup with a Class IIa CE-marked wound-care device wants to enter the US. Founders assume they need a full 510(k) with clinical data and are quoted 95,000 USD by their first consultant. They pause and ask for a second opinion.

Consultant two spends four billable hours reviewing the MDR technical file, the intended purpose, the clinical evaluation, and the product code landscape. The output is a two-page memo: the device is almost certainly Class I exempt under product code FRO, requires FDA establishment registration and device listing, a US Agent, and QMSR-aligned quality processes. No 510(k) needed. Labeling needs adjustment to meet 21 CFR 801 general requirements. Total cost to enter the US: roughly 12,000 USD in consulting, plus FDA establishment fees, plus internal time.

That four-hour memo saved the startup 80,000 USD and six months. This is what good US regulatory consulting looks like. The value is not in volume of work done; it is in correct pathway identification early.

The inverse also happens. Startups convinced they can self-certify into the US discover six months later that their software function makes them Class II under a specific product code and they need a 510(k) after all. By then they have been marketing in the US and receive a warning letter. The cost of this mistake dwarfs any consulting fee.

The Subtract to Ship playbook for hiring US RA consultants

Step one. Write down what you want the consultant to deliver, in one paragraph, before you talk to anyone. If you cannot articulate the deliverable, you are not ready to hire.

Step two. Source three candidates through specific channels, not LinkedIn search. Ask your Notified Body for referrals. Ask your EU investors who their portfolio companies used. Ask at AdvaMed, MedTech Europe or RAPS events. The quality of referrals beats the quality of websites.

Step three. Run a 30-minute screening call focused on three questions: 1. Walk me through the last three 510(k)s or De Novos you worked on for devices similar to ours. What was the product code, what was the predicate strategy, how long from kickoff to clearance? 2. How do you handle the relationship between our existing MDR technical documentation and the US submission? What do you reuse, what do you rebuild? 3. What is your experience with the QMSR transition? Have you helped ISO 13485-certified companies map their existing processes to the new FDA requirements?

A consultant who cannot answer these in specifics is not your consultant.

Step four. Ask for a sample deliverable. A good consultant has redacted sample sections of prior 510(k)s, gap analyses, or Pre-Submission packages they can share. Evaluate the writing. FDA reviewers read thousands of submissions; clarity wins.

Step five. Request a fixed-scope proposal. The proposal should list deliverables, milestones, payment structure, assumptions (what you provide), and explicit exclusions. Any item not on the proposal costs extra. This protects both sides.

Step six. Check references directly. Two references, both from the last 18 months, both EU-headquartered companies if possible. Ask: did the consultant meet deadlines, did they communicate proactively, did the final FDA submission need major revisions, would you hire them again?

Step seven. Negotiate the contract. Key clauses to insist on: - Milestone payments tied to deliverables, not time - Right to review all FDA correspondence before it is sent - Cap on hourly rate for out-of-scope work - Clear IP ownership of deliverables - Termination for cause with pro-rata payment - Confidentiality covering your device IP and business plans

Step eight. Set a weekly 30-minute sync during active work. Written status updates. No surprises.

Red flags

A consultant who promises a specific FDA clearance timeline ("90 days to clearance") is either lying or has never interacted with FDA. Timelines depend on FDA queue, device complexity, and questions raised during review.

A consultant who recommends a Pre-Submission meeting for every device is padding scope. Pre-Subs are valuable when genuine novelty or uncertainty exists, not as a standard first step.

A consultant who refuses to share redacted prior work samples does not have prior work worth showing.

A consultant who demands a large retainer before any deliverables is managing their cash flow at your expense.

A consultant whose fee structure is entirely hourly with no cap and no milestones will make the engagement as long as you let them.

A consultant who cannot explain QMSR in plain language, or who treats it as a trivial relabeling of 21 CFR 820, has not done the homework.

A consultant who ignores or dismisses your MDR technical documentation will rebuild work you have already paid for.

Reality Check

  1. Do you have a written, one-paragraph description of what you want the consultant to deliver?
  2. Do you know your likely US product code and classification, or is this part of the consultant's first deliverable?
  3. Have you mapped which sections of your MDR technical documentation can be reused for a US submission?
  4. Do you have at least three candidate consultants sourced from direct referrals, not cold search?
  5. Is your proposed engagement fixed-scope with milestone payments, or is it an open retainer?
  6. Have you checked two recent references who ran comparable engagements?
  7. Do you understand the QMSR transition timeline and how it affects your existing ISO 13485 processes?
  8. Have you set a budget ceiling and a no-go point if the consultant wants to exceed it?

Frequently Asked Questions

When is the right time for an EU startup to hire a US regulatory consultant? After you have a signed US commercial rationale (target customers, reimbursement view, distribution plan) and before you have committed engineering resources to US-specific changes. Hiring too early wastes money on exploratory work; hiring too late means rework.

Can our EU regulatory affairs person handle FDA submissions directly? Sometimes. If they have prior 510(k) or QSR experience, yes. If their background is purely MDR and ISO 13485, expect a steep learning curve. The FDA review culture, document expectations and language are different enough that a first-time submission without US-specific support is risky.

How much should we budget for US regulatory consulting? For a straightforward Class I exempt entry with QMSR gap analysis: 10,000 to 25,000 USD. For a 510(k) with clear predicate: 40,000 to 90,000 USD. For De Novo: 80,000 to 200,000 USD. PMA is a different universe. These numbers exclude FDA fees, testing, and your internal time.

Should the consultant also serve as our US Agent? Usually no. US Agent is a formal role that receives FDA correspondence. Bundling it with consulting creates a conflict when the consulting relationship ends. Use a dedicated US Agent service and keep the consulting separate.

Do we need a US consultant if we only sell through a US distributor? Yes. Distribution does not transfer regulatory obligations. You remain the manufacturer of record with FDA and must register, list, and meet QMSR. The distributor is not your regulatory shield.

What does QMSR transition actually mean for an ISO 13485-certified EU startup? QMSR aligns FDA quality system expectations with ISO 13485:2016. If your QMS is already genuinely 13485-compliant, the delta is small but non-zero: specific FDA terminology, certain record-keeping expectations, and labeling controls. A two to three week gap analysis by a QMSR-experienced consultant is usually enough to produce a remediation plan.

Sources

  1. US Food, Drug, and Cosmetic Act and 21 CFR Parts 800-898 (general device provisions, including 21 CFR 801 labeling).
  2. FDA Quality Management System Regulation (QMSR), final rule published 2 February 2024, transition deadline 2 February 2026.
  3. 21 CFR 807 Subpart E (510(k) premarket notification procedures).
  4. FDA De Novo Classification Request guidance (current version).